Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P18847: Variant p.Asn168Thr

Cyclic AMP-dependent transcription factor ATF-3
Gene: ATF3
Feedback?
Variant information Variant position: help 168 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Asparagine (N) to Threonine (T) at position 168 (N168T, p.Asn168Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and polar. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Found in a patient with childhood apraxia of speech; uncertain significance. Any additional useful information about the variant.


Sequence information Variant position: help 168 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 181 The length of the canonical sequence.
Location on the sequence: help LHRPTCIVRAQNGRTPEDER N LFIQQIKEGTLQS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         LH-------------------------------------------------------------------------RPT--------------------------------------------------------------------------------------------------------------------------------------------------CIVRA--------------QNGRT----------------------------------------------------PEDERNLFI------------QQIKEG----TLQS------------

Mouse                         LH--------------------------------

Rat                           LH--------------------------------

Bovine                        LH--------------------------------

Drosophila                    SHGCQRAGGCQLPSQLLQSPAQKYLSELELETVS

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 181 Cyclic AMP-dependent transcription factor ATF-3
Modified residue 162 – 162 Phosphothreonine
Cross 175 – 175 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Alternative sequence 116 – 181 KESEKLESVNAELKAQIEELKNEKQHLIYMLNLHRPTCIVRAQNGRTPEDERNLFIQQIKEGTLQS -> LQY. In isoform 2.
Alternative sequence 117 – 181 ESEKLESVNAELKAQIEELKNEKQHLIYMLNLHRPTCIVRAQNGRTPEDERNLFIQQIKEGTLQS -> LPRPFWVQKTCIWAVDSCK. In isoform 3 and isoform 4.



Literature citations
A set of regulatory genes co-expressed in embryonic human brain is implicated in disrupted speech development.
Eising E.; Carrion-Castillo A.; Vino A.; Strand E.A.; Jakielski K.J.; Scerri T.S.; Hildebrand M.S.; Webster R.; Ma A.; Mazoyer B.; Francks C.; Bahlo M.; Scheffer I.E.; Morgan A.T.; Shriberg L.D.; Fisher S.E.;
Mol. Psychiatry 24:1065-1078(2019)
Cited for: VARIANT THR-168;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.